We make LBPs to GMP pharmaceuticals standards.
Live Biotherapeutic Products are specifically a GMP pharmaceutical product and as such, we are a full cycle pharmaceutical CDMO.

At Biose Industrie we truly believe that health is managed thanks to the beneficial collaboration between human cells and microbes.

The Human Microbiome is responsible for regulating our immune system, producing essential vitamins, regulating our glucose levels and metabolism, protecting us against disease causing microbes and producing neurotransmitters that communicate with our brain. All of these factors can be manipulated or altered using LBPs.

“Just as importantly, the market potential for LBPs between now and 2025 is between €150M and €250M and once drugs get to market, the potentiel is over €1B+ by 2035.”

LBPs are not only about intestinal delivery, but also the skin with creams and oils, the vagina with creams, ovules or tablets, and more recently, the nose, mouth, throat and lungs.

We are convinced that the future is bright for LBPs and our position as the only end-to-end CDMO currently producing clinical material under one roof, provides us with a major advantage in assisting our clients through clinical trials and more importantly, treating patients.